ISSN: 2581-5989
PubMed - National Library of Medicine - ID: 101738774

International Journal of Dental Science and Innovative Research (IJDSIR)

IJDSIR : Dental Publication Service

Available Online at:www.ijdsir.com

Volume – 8, Issue – 2, March – 2025, Page No. : 77 - 84

Smart Safety: How AI is Transforming Drug Monitoring

[1]Dr Charu Rawat, BDS, Goregaon Dental Centre, India

[2]Dr Varsha Aher, MDS, OMDR, Goregaon Dental Centre, India, India

[3]Dr Amrita Dharmendra Batho, MDS Periodontology, Goregaon Dental Centre, India

[4]Dr Harshvardhan N Jain, BDS, MCP, FAD, One Dental Place, India

[5]Dr Anoli Agrawal, MDS, Public Health Dentistry, Assistant Professor, Department of Public Health Dentistry, ACPM Dental College, Dhule, Goregaon Dental Centre, India

Corresponding Author: Dr Charu Rawat, BDS, Goregaon Dental Centre, India

Citation of this Article: Dr Charu Rawat, Dr Varsha Aher, Dr Amrita Dharmendra Batho, Dr Harshvardhan N Jain, Dr Anoli Agrawal, "Smart Safety: How AI is Transforming Drug Monitoring", IJDSIR- March – 2025, Volume – 8, Issue – 2, P. No. 77 – 84.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Ensuring the safety of newly launched drugs remains a major challenge in pharmacology, with adverse events contributing to unnecessary morbidity and mortality. Traditional methods, including clinical trials and post-marketing pharmacovigilance, are not error-proof, often failing to detect rare adverse events or drug-drug interactions. Artificial intelligence (AI) has emerged as a transformative tool in healthcare, driven by advancements in machine learning (ML) and deep learning (DL). In pharmacology, AI facilitates target identification, lead compound screening, AI-Guided Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) prediction, and personalized dosage optimization. AI models predict drug efficacy and safety, detect adverse drug events, and optimize treatment outcomes, thus advancing personalized medicine and precision pharmacotherapy. However, challenges such as data quality, ethical concerns, regulatory compliance, and the need for algorithmic validation hinder its widespread adoption. While AI technologies significantly enhance pharmacovigilance systems, they cannot replace the expert judgment of clinical professionals. A balanced approach, integrating AI with human expertise and robust regulatory frameworks, is essential for achieving safer drug use and improved healthcare outcomes.

Keywords: Artificial intelligence, Pharmacovigilance, Risk assessment, Dosage optimization, Adverse drug events

Introduction

The major challenge in launching a new drug into the market lies in ensuring its safety. Adverse events or drug

reactions that lead to unnecessary morbidity and mortality remain a significant issue.

Between 2014 to 2024 the Food and Drug Administration (FDA) has approved 215 novel drugs. Around 10 million cases of adverse events were reported by the FDA Adverse Event Reporting System (FAERS) over the same period of time. This has resulted in greater strain on the healthcare system by increasing admission rates and longer hospital stays causing significant public health concern.

To evaluate the safety of the drug generally two systems are used. The first one is to assess during the clinical trials and the second one is monitoring the safety after it's marketed, a process called pharmacovigilance.[1] But neither of the systems are error proof. Like for example it is not possible to conduct trials on a large population to detect uncommon adverse events because often the drugs designed are primarily focused for an average patient despite growing calls for precision medicine ensuring the "right drug at the right dose for the right patient".[2] Once drugs receive approval it becomes the responsibility of monitoring programs to oversee their safety. These agencies rely on databases of spontaneously collected adverse event reports to identify potential issues and conduct follow-up analyses. However these reports are prone to biases, such as underreporting for rare events which is particularly problematic and drug-drug interactions. To address these challenges the research community has increasingly turned to statistical and computational methods using artificial intelligence to enhance pharmacovigilance efforts.

Merriam- Webster defines artificial intelligence as "A branch of computer science dealing with the simulation of intelligent behaviour in computers;[2] the capability of a machine to imitate intelligent human behaviour"

Artificial intelligence in healthcare has undergone remarkable evolution. Over the past two decades two significant developments have occurred :[1] The widespread availability of freely accessible databases of medical, chemical , and pharmacological knowledge alongside the swift adoption of electronic health record (EHR) systems driven by the Health Information Technology for Economic and Clinical Health (HITECH) Act; and[2] the emergence of advanced computational techniques in machine learning (ML) and deep learning (DL) which is a rebranded form of neural networks fuelled by rapid increase in compute power and data availability.

The promising ability of artificial intelligence in healthcare has gained significant attention with potential applications across various areas of medicine. This potential of artificial intelligence is been welcomed in healthcare systems worldwide to achieve the "quadruple aim" namely to improve experience of care, improving the health of populations, reducing per capita costs of healthcare, and improving the work life of healthcare providers.[3] The introduction of machine learning and deep learning has broadened artificial intelligence's scope allowing for more personalized approaches to medicine moving beyond traditional algorithms.

The aim of this is to highlight the potential of artificial intelligence in pharmacology for more accurate detection, prediction, and prevention of adverse drug events (ADEs) enhancing patient safety and additionally addressing the challenges that come with adopting AI in pharmacovigilance.

Material and Methodology

To review the literature, studies were selected from PubMed, Scopus, Web of Science, and Google Scholar without restrictions on publication year, to provide a comprehensive overview of current knowledge on the

application of artificial intelligence in pharmacovigilance and drug safety. The review focused on evaluating AI methodologies for detecting, predicting, and preventing adverse drug events, as well as their role in enhancing drug development and personalized medicine. The search terms included: "Artificial intelligence," "Machine learning," "Pharmacovigilance," "Drug safety," "Adverse drug events". The research encompassed case reports, laboratory studies, clinical studies, systematic reviews.

Application of Artificial Intelligence in Pharmacology

The application of machine learning (ML), particularly deep learning (DL) methods such as convolutional neural networks (CNNs) and natural language processing (NLP), has transformed critical stages of drug discovery, development, and post-marketing surveillance.



Application of artificial intelligence in pharmacological research

Drug discovery and development

The process of drug discovery and development plays a vital role in identifying new therapeutic targets, screening potential lead compounds, and evaluating drug efficacy and safety. In recent years, artificial intelligence (AI) has become a transformative tool in these areas, revolutionizing the traditional approaches to drug discovery.

AI in Target Identification and Validation

Artificial Intelligence (AI) is revolutionizing target identification and validation in drug discovery by leveraging vast datasets and advanced computational power. The algorithms analyze diverse data sources, including genomics, proteomics, and clinical datasets, to uncover and validate promising therapeutic targets. AI-driven approaches in target identification and validation include:

1. Statistical Analysis-Based Approaches: These methods utilize omics data, such as genome-wide association studies (GWAS) and summary data-based Mendelian randomization (SMR), to identify disease-associated candidate target genes. [4]
2. Network-Based Approaches: Network-based methods explore intricate biological connections by leveraging gene co-expression and miRNA-disease networks to identify disease-associated gene sets and miRNA-disease associations within pathways. Knowledge graphs, which integrate entities, relationships, and semantic information, further enhance data representation and analysis. [5]
3. Machine Learning-Based Approaches: ML techniques, such as classifiers (e.g., random forests, support vector machines, and neural networks) and regression models, predict whether a gene is a viable drug target.

AI models also validate potential targets by predicting their druggability and assessing their suitability for therapeutic intervention. [6] This reduces reliance on experimentally validated hypotheses, enabling the exploration of previously untapped targets and advancing the drug discovery process.

AI-Driven Virtual Screening for Lead Compound Identification

AI is transforming virtual screening by accelerating the identification of lead compounds. Advanced models analyze extensive chemical databases to predict the likelihood of compound-target binding. This approach efficiently prioritizes high-affinity compounds with favorable pharmacokinetic properties, streamlining the drug discovery process.

The two main approaches to virtual screening are:[1] structure-based approaches - molecular docking simulations and [2] Ligand-based approaches assuming compounds with similar structures interact with the same target. In addition to these approaches, chemogenomic methods integrate data on target proteins and chemical compounds to predict drug-target interactions (DTIs), enhancing the efficiency and accuracy of lead compound identification. Recently Evotec, a German biotech firm, collaborated with Exscientia, a UK-based AI-driven drug discovery company, to accelerate drug development. Leveraging Exscientia's "Centaur Chemist" AI design platform, they identified a promising anti-cancer drug candidate in just eight months—significantly faster than traditional methods.

The AI system analysed millions of molecules, narrowing them down to a select few for synthesis, testing, and optimization, ultimately producing a candidate ready for clinical trials. [7]

AI-Guided Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Prediction

AI techniques play a crucial role in predicting key ADMET properties—absorption, distribution, metabolism, excretion, and toxicity of drug. Predictive models leverage both engineered and learned molecular descriptors to accurately forecast properties such as human intestinal absorption (HIA), aiding in the selection of compounds with optimal pharmacokinetic and safety profiles.

Prediction of Drug Efficacy and Safety Using AI Models

AI models harness data from preclinical and clinical studies to predict various drug properties. By utilizing machine learning (ML) algorithms, these models analyze extensive datasets to identify molecular features linked to therapeutic response and toxicity. This helps in selecting promising drug candidates with better efficacy and safety profiles.

Pharmacoepidemiology and Pharmacovigilance

AI technologies are transforming pharmacovigilance by improving drug safety monitoring through the analysis of real-world data. Using machine learning (ML) and natural language processing (NLP), AI models can predict and detect adverse drug events (ADEs), enhancing the identification of medication-related issues from diverse data sources such as electronic health records and pharmacovigilance databases. Additionally, AI improves the efficiency and consistency of processing individual case safety reports (ICSRs), automating manual tasks, reducing bias, and offering valuable insights for data scientists and healthcare professionals.

AI's role in pharmacovigilance extends beyond data analysis to include adverse event detection, risk assessment, and signal detection in post-marketing surveillance. Automation accelerates the processing of adverse event cases, including extracting information from source documents and evaluating case validity, thus enhancing the efficiency and quality of pharmacovigilance operations.

AI Models for Predicting Drug Response and Optimizing Treatment Outcomes

AI models enhance treatment outcomes by predicting drug responses through machine learning (ML) algorithms and analyzing diverse biomedical data. These models identify molecular signatures and phenotypic changes associated with drug response, facilitating personalized therapies and drug repurposing. AI also reveals the biological mechanisms behind drug responses, aiding in the development of new therapeutics and targeted interventions. By improving predictions of drug efficacy and safety, AI models contribute to higher success rates in clinical trials.

Integration of Genomic Data and AI Algorithms for Personalized Drug Selection

The integration of genomic data with AI algorithms enables more accurate, personalized drug selection by analysing genetic variants linked to drug response and adverse reactions. This approach enhances personalized medicine by helping avoid ineffective or harmful medications for specific patients.

Personalized care is particularly crucial in epilepsy treatment, as about 30% of patients do not achieve adequate control with current anti-epileptic drugs (AEDs). This results in challenges such as comorbidities, reduced quality of life, increased mortality risk, and higher treatment costs. To address these challenges, a comprehensive understanding and prediction of AED responses are essential. Previous research has mainly focused on genes related to drug metabolism, overlooking other genetic factors and disease mechanisms. A more holistic approach that considers multiple factors is required in precision medicine. [8]

AI-Guided Dosage Optimization for Individual Patients

AI-driven dosage optimization plays a critical role in precision pharmacotherapy. By analyzing patient-specific characteristics, such as age, comorbidities, and clinical data, alongside biomarkers, AI algorithms determine the most effective drug dosages. Machine learning (ML) techniques identify patterns and correlations within this data, enabling the creation of personalized dosing regimens that improve both efficacy and safety.

Challenges of Adoption of Artificial Intelligence in Pharmacovigilance

Scientific Challenges

AI implementation in pharmacovigilance (PV) faces several challenges related to interpretation, prediction, and accountability. The process of adverse event (AE) case processing in PV is inherently complex, involving multiple decision points and adjudication within regulated and audited frameworks. While clinical evaluation and expert judgment play pivotal roles in causality assessment and signal detection, these tasks remain highly reliant on human intervention due to the variability in clinical presentations and adverse effects. [9]

The lack of standardization in the assessment of Individual Case Safety Reports (ICSRs) poses another significant challenge. Current AI tools are not yet robust enough to fully determine temporality, establish causal associations, predict drug-drug interactions, or flag safety alerts with the reliability required for real-world data processing. Moreover, full automation carries inherent risks, including the possibility of false positives and errors that waste time and resources.[10] It also raises critical questions about accountability: if an AI system makes an error despite validation, responsibility could fall on developers, technology firms, or regulators. Importantly, researchers caution against the indiscriminate use of AI in pharmacovigilance, emphasizing that these tools should complement, not replace, expert clinical judgment in complex case

scenarios. To ensure safe and effective adoption, AI technologies must remain flexible, harmonized with best practices, and integrate seamlessly with clinical expertise, particularly for challenging or ambiguous cases in pharmacovigilance.

Technological Challenges

Training Datasets and Validation

The foundation of AI technology lies in the quality and comprehensiveness of the training datasets used to develop its algorithms. These datasets must be vast, diverse, and sourced from various platforms, encompassing all types of adverse event (AE) reports and representing the global population to ensure the algorithm's validity and robustness in real-world scenarios.[11] The training models must undergo rigorous testing and validation before being applied to real-world data. To build a robust dataset, spontaneous AE reports must be integrated with data from electronic health records in both public and private hospitals, outpatient clinics, general practice records, disease registries, and published medical literature. This integration would provide high-quality evidence for causal association and signal detection. To achieve accurate predictions, training datasets must be comprehensive, encompassing data from both public and private healthcare sectors, representing diverse diseases and therapeutic areas, and including sufficient numbers of patients from all ethnic and demographic groups. Without such inclusivity, AI predictions may be misleading, inaccurate, and fail to meet the needs of diverse populations. From an algorithmic perspective, AI models used in pharmacovigilance (PV) must exhibit high sensitivity, specificity, consistency, validity, and reproducibility to accurately flag potential drug safety signals. Given the rapid advancements in medical science and therapeutics, AI algorithms must be dynamic, capable of regular updates, retraining, and revalidation.

Technical Considerations

Pharmacovigilance (PV) faces numerous technical challenges related to the variability and ambiguity of medical language, data integration, and labelling. Differences in drug and disease names, descriptions of adverse drug effects, regional language diversity, and the lack of detailed information on self-medication practices pose significant hurdles in processing PV data accurately. A major issue lies in language ambiguity and the multiple meanings or interpretations of medical terms.[12] For instance, "skin rashes" can result from over 20 different causes, including drug-induced reactions. To accurately identify, differentiate, and diagnose such conditions, critical details like the location, description, and associated signs and symptoms must be provided. Inconsistent definitions of "skin rashes" as an adverse event (AE) across different sources can lead to erroneous decisions and outcomes. Similar challenges arise when different terms, such as "skin rash" versus "erythema" or "hypotension" versus "orthostatic hypotension," are used to describe the same reaction, causing confusion and inaccuracies.

Although AI tools can be trained to understand the various meanings of a medical term, they may struggle to grasp the precise context in which the term is used. This highlights the importance of establishing standardized case definitions to ensure consistent interpretation and accurate decision-making, especially when descriptions and interpretations differ between reporters. Additionally, social media has emerged as a potential data source for PV but brings its own set of challenges. Nonstandard terminology, slang, spelling errors, abbreviations, and incomplete information often found on social media platforms limit its reliability and

usability for detecting AEs. Addressing these issues is critical for improving the accuracy and utility of AI-driven PV systems.

Ethical Concerns

A major ethical challenge in AI-driven pharmacovigilance is ensuring the proper access, ownership, and use of individual patient data. Without adequate regulations and explicit patient consent, there is a risk of compromising privacy, raising ethical concerns, and undermining trust in the doctor-patient relationship.[13] To address these concerns, it is essential that patients' personal data, sensitive information, and images used for research are obtained with informed consent and anonymized to protect their identities. This ensures ethical handling of data while maintaining confidentiality and fostering responsible use in pharmacovigilance efforts. Robust data governance frameworks are necessary to uphold these standards and build public trust in the integration of AI in healthcare.

Regulatory Concerns

AI technologies used for clinical predictions, diagnoses, prevention, and treatment of diseases are classified as medical devices, such as Clinical Decision Support tools, and are regulated by the US Food and Drug Administration (FDA).[14] However, recent reports indicate that the evidence supporting FDA approval for certain critical care medical devices has not consistently met the standards for independent validation or clinical efficacy. This highlights the pressing need for preapproval studies to validate the safety, efficacy, and reliability of AI-based devices, particularly those developed prior to the advent of advanced statistical learning methods. In India, while the Indian Council of Medical Research (ICMR) has introduced ethical guidelines for the application of AI in biomedical research and healthcare, there are currently no specific laws regulating AI use. [12] Similarly, AI adoption for automating pharmacovigilance (PV) systems lacks a clear regulatory framework. Such regulations are crucial to ensure validation, accuracy, and safety when applying AI technologies in real-world settings, especially for diverse patient populations. Moreover, regulations must balance commercial interests and transparency among technology developers while prioritizing patient safety and public well-being. Regulatory frameworks must also evolve to address the challenges of adaptive AI systems, which require certification and reapproval as they integrate new data and undergo updates. Establishing this dynamic process will be essential to maintain trust and efficacy in AI applications over time. Additionally, the successful integration of AI in PV demands significant investment in infrastructure, including research and development, educational resources for training healthcare professionals, and robust data systems to build comprehensive patient databases.

Conclusion

Recent advances in artificial intelligence (AI) offer impressive potential for healthcare, particularly in well-defined tasks like medical image interpretation. However, its application to more complex and heterogeneous data, such as pharmacovigilance (PV) systems, is more challenging. While AI tools can significantly reduce manual workload and increase efficiency in PV, they cannot replace the essential role of medical review and the judgment of trained PV professionals, especially in the final adjudication of causality and signal detection. Full automation of the PV system introduces risks and challenges, requiring extensive testing, validation, and approval from both medical professionals and regulators. Furthermore, AI experts often do not fully understand the intricacies of interpreting medical data, while healthcare professionals

may lack familiarity with AI technology. Thus, AI should aim to enhance human intelligence, not replace it. To maximize its benefits in PV, AI must complement human expertise, ensuring improvements in the quality of care, efficiency, and patient outcomes, while mitigating potential risks and challenges. The development of thoughtful regulatory frameworks will be essential to support AI's safe and effective integration into clinical settings.

References

1. Basile AO, Yahi A, Tatonetti NP. Artificial intelligence for drug toxicity and safety. Trends in pharmacological sciences. 2019 Sep 1;40(9):624-35.
2. Collins FS, Varmus H. A new initiative on precision medicine. New England journal of medicine. 2015 Feb 26;372(9):793-5.
3. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff. 2008;27:759–69.
4. Kim H, Kim E, Lee I, Bae B, Park M, Nam H. Artificial intelligence in drug discovery: a comprehensive review of data-driven and machine learning approaches. Biotechnology and Bioprocess Engineering. 2020 Dec;25:895-930.
5. You Y, Lai X, Pan Y, Zheng H, Vera J, Liu S, Deng S, Zhang L. Artificial intelligence in cancer target identification and drug discovery. Signal Transduction and Targeted Therapy. 2022 May 10;7(1):156.
6. Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ precision oncology. 2020 Jun 15;4(1):19.
7. Savage N. Tapping into the drug discovery potential of AI. Nature. com. https://www. nature. com/articles/d43747-021-00045-7. 2021.
8. Singh S, Kumar R, Payra S, Singh SK. Artificial intelligence and machine learning in pharmacological research: bridging the gap between data and drug discovery. Cureus. 2023 Aug;15(8).
9. Agbabiaka TB, Savović J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug safety. 2008 Jan;31:21-37.
10. Van Noorden R, Perkel JM. AI and science: what 1,600 researchers think. Nature. 2023 Sep 1;621(7980):672-5.
11. Mockute R, Desai S, Perera S, Assuncao B, Danysz K, Tetarenko N, Gaddam D, Abatemarco D, Widdowson M, Beauchamp S, Cicirello S. Artificial intelligence within pharmacovigilance: a means to identify cognitive services and the framework for their validation. Pharmaceutical medicine. 2019 Apr 1;33:109-20.
12. Desai MK. Artificial intelligence in pharmacovigilance–Opportunities and challenges. Perspectives in Clinical Research. 2024:10-4103.
13. Kumar R, Sharma P, Singha M, Singh J. Big Data Analytics and Pharmacovigilance—An Ethical and Legal Consideration. AMEI's Current Trends in Diagnosis & Treatment. 2018 Jun 1;2(1):58-65.
14. Lee JT, Moffett AT, Maliha G, Faraji Z, Kanter GP, Weissman GE. Analysis of devices authorized by the FDA for clinical decision support in critical care. JAMA Internal Medicine. 2023 Dec 1;183(12):1399-401.